REPLIGEN CORP 8K

Repligen Corporation reported solid Q2 2026 results, raised its full-year 2026 revenue and adjusted EPS guidance, and highlighted a definitive agreement to acquire BioLife Solutions and other strategic initiatives.

On July 28, 2026, Repligen Corporation reported its financial results for the second quarter ended June 30, 2026, highlighting 12% year-over-year reported revenue growth to $204 million (13% organic), modestly higher GAAP operating income but significantly higher adjusted operating income and margins, and raised full-year 2026 guidance for organic revenue growth and adjusted diluted EPS. The company also discussed key business developments, including the announcement of a definitive agreement to acquire BioLife Solutions to strengthen its cell therapy consumables platform, the opening of a Repligen Training Innovation Center in the Netherlands, and the publication of its 2025 Sustainability Report. Updated 2026 non-GAAP guidance now calls for total revenue of $813–$835 million (10%–13% reported growth, 10.5%–13.5% organic), adjusted operating margin of 15.7%–16.0%, adjusted EBITDA margin of 20.6%–21.0%, and adjusted diluted EPS of $2.03–$2.09, supported by a strong liquidity position with $810 million in cash, cash equivalents and marketable securities as of June 30, 2026.

Filing Facts

CIK

730272

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-318853

Alert Tier

7